Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charlie Reavill

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Bioorganic & Medicinal Chemistry Letters|February 16, 2010
The identification of a selective dopamine D2 partial agonist, D3 antagonist displaying high levels of brain exposureIan P Holmes, Richard J Blunt, Olivier E Lorthioir, et al.
Journal of Medicinal Chemistry|October 31, 2003
Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonistGregor J Macdonald, Clive L Branch, Michael S Hadley, et al.
Bioorganic & Medicinal Chemistry Letters|November 7, 2006
Studies towards the identification of a new generation of atypical antipsychotic agentsVincenzo Garzya, Ian T Forbes, Andrew D Gribble, et al.
Genetica|December 29, 2004
Towards a mutant map of the mouse--new models of neurological, behavioural, deafness, bone, renal and blood disordersSohaila Rastan, Tertius Hough, Amy Kierman, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Bioorganic & Medicinal Chemistry Letters|February 16, 2010
The identification of a selective dopamine D2 partial agonist, D3 antagonist displaying high levels of brain exposureIan P Holmes, Richard J Blunt, Olivier E Lorthioir, et al.
Journal of Medicinal Chemistry|October 31, 2003
Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonistGregor J Macdonald, Clive L Branch, Michael S Hadley, et al.
Bioorganic & Medicinal Chemistry Letters|November 7, 2006
Studies towards the identification of a new generation of atypical antipsychotic agentsVincenzo Garzya, Ian T Forbes, Andrew D Gribble, et al.
Genetica|December 29, 2004
Towards a mutant map of the mouse--new models of neurological, behavioural, deafness, bone, renal and blood disordersSohaila Rastan, Tertius Hough, Amy Kierman, et al.
Pageof 2